Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 65,000 shares, a decrease of 32.0% from the November 15th total of 95,600 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.5% of the company’s stock are sold short.

Tharimmune Trading Down 1.8 %

Shares of Tharimmune stock traded down $0.04 on Friday, hitting $2.14. 20,794 shares of the company’s stock were exchanged, compared to its average volume of 359,459. Tharimmune has a 1 year low of $1.84 and a 1 year high of $8.55. The company has a 50-day simple moving average of $2.28 and a 200-day simple moving average of $2.93.

Institutional Trading of Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC bought a new stake in shares of Tharimmune, Inc. (NASDAQ:THAR) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on THAR shares. RODMAN&RENSHAW upgraded shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th. Rodman & Renshaw assumed coverage on shares of Tharimmune in a report on Friday, December 6th. They set a “buy” rating and a $17.00 price target on the stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).